In a report issued on July 18, Mani Foroohar from SVB Securities maintained a Hold rating on Wave Life Sciences (WVE – Research Report), with a price target of $3.00. The company’s shares closed last Tuesday at $2.70.
According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -18.1% and a 38.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Recursion Pharmaceuticals.
Wave Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
The company has a one-year high of $6.64 and a one-year low of $1.16. Currently, Wave Life Sciences has an average volume of 546.4K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of WVE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Read More on WVE:
- SVB Securities Keeps a Hold Rating on Talaris Therapeutics (TALS)
- United Parcel (UPS) Receives a Hold from J.P. Morgan
- Evercore ISI Maintains a Hold Rating on CommScope Holding (COMM)
- Analysts Offer Insights on Financial Companies: Deutsche Bank AG (DB) and UBS Group AG (UBS)
- Bluebird Bio (BLUE) Receives a Hold from SVB Securities